Skip to main content
Premium Trial:

Request an Annual Quote

September Plans

The US Food and Drug Administration is aiming grant full approval to the Pfizer-BioNTech SARS-CoV-2 vaccine by Labor Day, according to the New York Times.

The agency has been under pressure to fully approve SARS-CoV-2 vaccines, especially as the number of Delta variant-driven cases has increased. The vaccines in use in the US are currently available under Emergency Use Authorizations but Pfizer and BioNTech as well as Moderna are seeking approval for their vaccines. Pfizer and BioNTech, the Wall Street Journal noted the other day, have finished submitting the needed paperwork. According to the Washington Post, Peter Marks, director of the FDA's Center for Biologics Evaluation and Research, the FDA is moving at a "sprint" to work toward approval.

The Times now reports that the agency has a deadline of early September in mind. It notes that approval requires additional data than an EUA — regulators, it adds, are interested in real-world data on how the vaccine has worked when administered under the EUA — and that a priority review generally takes six to eight months.

Full approval could spark additional vaccine mandates as well as give doctors the ability to prescribe additional shots for individuals with compromised immune systems, the Times adds. Pfizer is also expected soon to seek authorization for a vaccine booster, the need for which is still unclear.

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.